The Federal Trade Commission reached a settlement with Amgen that would allow the drugmaker to acquire Horizon Therapeutics and dismisses the antitrust claims of six states.
Amgen says it expects to quickly seek the final approval needed to close its transaction for Horizon Therapeutics.
WASHINGTON—The Federal Trade Commission said Friday it reached an agreement that would end its legal challenge of drugmaker, averting a trial that was to have started this month.Continue reading your article with
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
FTC allows Amgen to move forward with $27.8 billion Horizon Therapeutics acquisitionThe FTC had filed a lawsuit in May seeking to block the acquisition, arguing that the deal would 'stifle competition' in the pharmaceutical industry.
Lire la suite »
FTC settles with Amgen over $27.8 billion takeover of Horizon TherapeuticsThe Federal Trade Commission reached a deal with Amgen Inc. to approve its $27.8 billion acquisition of Horizon Therapeutics plc, the agency announced...
Lire la suite »
FTC Settles With Amgen Over $27.8 Billion Deal for Horizon TherapeuticsThe Federal Trade Commission reached a settlement with Amgen that would allow the drugmaker to acquire Horizon Therapeutics and dismisses the antitrust claims of six states.
Lire la suite »
Amgen and Horizon Therapeutics Stocks Rise After FTC Settlement Over $27.8 Billion MergerThe Federal Trade Commission makes provision that prohibits “bundling” discounts for some medications.
Lire la suite »